INTERSTITIAL LUNG DISEASE MARKET ANALYSIS

Interstitial lung disease (ILD) is another term for pulmonary fibrosis, which means “scarring” and “inflammation” of the interstitium (the tissue that surrounds the lung’s air sacs, blood vessels and airways). This scarring makes the lung tissue stiff, which can make breathing difficult. ILD may be limited to the lung, or it can be related to a condition that may affect other parts of the body, such as rheumatoid arthritis or sarcoidosis. Most people with interstitial lung disease have symptoms that makes breathing difficult, such as:

• Shortness of breath
• Coughing
• Decreased exercise tolerance
• Fatigue
• Weight loss

For instance, according to a report published 2017, in European Respiratory Journal, 1170 interstitial lung disease cases were reported. The overall prevalence was 97.9 and incidence: 19.4/year in Paris and France. The most prevalent diagnoses were sarcoidosis (42.6%), connective tissue diseases associated ILDs (CTDs-ILDs) (16%), idiopathic pulmonary fibrosis (IPF) (11.6%), and occupational ILDs (5.0%).

Global Interstitial Lung Disease Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector, which has been majorly impacted by the pandemic. Cancer patients in general and those suffering from lung cancer in particular are a vulnerable group because of their various intrinsic characteristics and care needs. Lung cancer patients require frequent radiologic study follow-ups, which had been affected due to COVID-19 pandemic. COVID-19 related incidental radiologic findings can appear in routinely scheduled radiology tests, which may be difficult to interpret. Moreover, cancer treatment induced pneumonitis may have similar radiologic features similar to those in acute SARS-CoV-2 pneumonia and lead to a wrong diagnosis. The different health care needs, the requirement for continuous health care access and follow-ups, and the clinical trials in which this patient population might be enrolled are all being affected by the current COVID-19 health crisis. Due to COVID-19 pandemic health care providers and institutions faced difficult situations and challenging ethical scenarios.

The global interstitial lung disease market is estimated to be valued at US$ 1,578.9 Mn in 2021 and is expected to exhibit a CAGR of 6.5% over the forecast period (2021-2028).

Figure 1: Global Interstitial Lung Disease Market Share (%) Analysis, By Disease Type, 2021

To learn more about this report, Request sample copy

Increasing number of drug approvals from regulatory bodies is a major factor driving the market growth over the forecast period.

Market players are focusing on gaining drug approvals from regulatory bodies, which is expected to drive the growth of global interstitial lung disease market during the forecast period. For instance, in April 2021, United Therapeutics Corporation, a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved Tyvaso (treprostinil) Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease to improve exercise ability.  

Adoption of inorganic strategies by the market players is expected to drive the market growth during the forecast period.

Increasing number of partnerships by key players are expected to boost the growth of global interstitial lung disease market during the forecast period. For instance, in September 2020, Boehringer Ingelheim (Canada) Ltd., a pharmaceutical company, announced that they had entered into partnership with the University Hospital Foundation (UHF), this partnership will focus on improving patient outcomes in the area of progressive fibrosing interstitial lung disease (PF-ILD).

Global Interstitial Lung Disease Market – Restraints

Lack of awareness related to interstitial lung disease is expected to hinder the growth of the global interstitial lung disease market during the forecast period.

For instance, in August 2021, an educational webinar was held to drive awareness of interstitial lung disease (ILD), nine organizations collaborated to present the first-ever Interstitial Lung Disease Day (ILD) on, September 15. ILD is a term which refers to more than 200 types of lung diseases, which are characterized by inflammation and scarring in the lungs. The inflammation and scarring injures the lungs, making it difficult to breathe. Nine organizations include Pulmonary Fibrosis Foundation, Arthritis Foundation, Foundation for Sarcoidosis Research, The Myositis Association, PF Warriors LLC, Scleroderma Foundation, Scleroderma Research Foundation, Sjögren’s Foundation, Inc., and WESCOE Foundation.

Global Interstitial Lung Disease Market – Regional Analysis

On the basis of region, the global interstitial lung disease market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global interstitial lung disease market, owing to increasing number of drug approvals by regulatory bodies.

For instance, in March, 2021, F. Hoffmann-La Roche Ltd, a biotech company, announced that the U.S. Food and Drug Administration (FDA) approved Actemra/RoActemra (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the US FDA for the treatment of the disease.

Figure 2: Global Interstitial Lung Disease Market Value (US$ Mn), By Region, 2020

To learn more about this report, Request sample copy

Global Interstitial Lung Disease Market – Competitive Landscape

Major players operating in the global interstitial lung disease market include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd, Inc., and Cipla.